A drug used by smokers to help them quit increases the risk of heart attacks and other serious cardiovascular problems, research says. An international team reviewed studies involving more than 8,000 smokers, and found more of those taking Champix fell ill than those on dummy drugs. The review, in the Canadian Medical Association Journal, suggests smokers should not use the drug to stop. But makers Pfizer say it is an "important option" to help people quit. And heart experts stress smoking itself is a major heart disease risk factor. Champix (varenicline) accounted for over 955,000 prescriptions in England last year. It works by cutting cravings, but in the past it has been linked to depression and suicidal thoughtsThis is the blog for CARG, the Coronary Artery Rehabilitation Group, based in Saskatoon, Saskatchewan, Canada. It will contain items of interest to CARG's own members and anybody else interested in the latest news about rehabilitation and heart-related matters. Canadian charitable number: 89675 0163 RR 0001 || e-mail: carg.ca@gmail.com || website: carg.ca || Blog disclaimer
Friday, July 8, 2011
'Quit smoking' drug linked to heart risk
A drug used by smokers to help them quit increases the risk of heart attacks and other serious cardiovascular problems, research says. An international team reviewed studies involving more than 8,000 smokers, and found more of those taking Champix fell ill than those on dummy drugs. The review, in the Canadian Medical Association Journal, suggests smokers should not use the drug to stop. But makers Pfizer say it is an "important option" to help people quit. And heart experts stress smoking itself is a major heart disease risk factor. Champix (varenicline) accounted for over 955,000 prescriptions in England last year. It works by cutting cravings, but in the past it has been linked to depression and suicidal thoughts
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment